Ranibizumab administration is by intravitreal injection.

- For NVAMD treatment therapy, 0.5 mg (0.05 mL) is recommended as an intravitreal injection once a month.

- For macular edema treatment following RVO, 0.5 mg (0.05 mL) is recommended as an intravitreal injection once a month.

- For the treatment of DME and DR, 0.3 mg (0.03 mL) is recommended as an intravitreal injection once a month.

- For the treatment of mCNV, 0.5 mg (0.5 mL) is recommended as an intravitreal injection once a month for no more than three months.

- Acute treatment administration may be with variably prescribed injection protocols.